Grifols, S.A. (NASDAQ:GRFS – Get Free Report)’s share price gapped up before the market opened on Tuesday . The stock had previously closed at $8.34, but opened at $8.73. Grifols shares last traded at $8.67, with a volume of 139,494 shares changing hands.
Grifols Stock Up 7.0 %
The company has a market cap of $6.03 billion, a price-to-earnings ratio of 8.68 and a beta of 0.50. The stock has a 50-day simple moving average of $8.82 and a 200-day simple moving average of $7.77. The company has a current ratio of 1.68, a quick ratio of 0.80 and a debt-to-equity ratio of 1.06.
Grifols (NASDAQ:GRFS – Get Free Report) last announced its earnings results on Tuesday, July 30th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.21). The company had revenue of $1.96 billion for the quarter. As a group, analysts predict that Grifols, S.A. will post 0.79 EPS for the current year.
Institutional Trading of Grifols
About Grifols
Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.
Further Reading
- Five stocks we like better than Grifols
- NYSE Stocks Give Investors a Variety of Quality OptionsÂ
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- Trading Halts Explained
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.